Finalized Consent Decree For Allston Largely In Line With Genzyme's Expectations
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech will pay an upfront disgorgement of $175 million from past profits on drugs made at Allston; must transfer all fill/finish out of troubled facility by end of November.
You may also be interested in...
Fabrazyme Patients Ask FDA To Retool Genzyme's Product Distribution Plan
If the agency stops Genzyme from exporting its Fabry disease treatment Fabrazyme (agalsidase beta), there will be enough for U.S. patients, a citizen petition says.
Fabrazyme Patients Ask FDA To Retool Genzyme's Product Distribution Plan
If the agency stops Genzyme from exporting its Fabry disease treatment Fabrazyme (agalsidase beta), there will be enough for U.S. patients, a citizen petition says.
Genzyme Jumps First Consent Decree Hurdle
Genzyme - out to assure investors and hostile bidder Sanofi that its business is back on track - says it successfully met the first requirement of an FDA consent decree.